The Washington State Department of Health implemented an emergency closure and recall for shellfish harvested from Drayton Harbor after raw oysters were linked to an outbreak of norovirus-like ...

Some individuals with IBS meet the criteria for nonceliac gluten sensitivity and may find symptom improvement with a gluten-free diet.

Risankizumab subcutaneous induction therapy appears to be efficacious against moderate to severe Crohn disease (CD), reinforcing it as an effective treatment option in patients with active disease.

The FDA expands Palynziq approval to include pediatric patients aged 12 years and older with phenylketonuria and uncontrolled blood Phe levels.

The table below is a review of notable updates that occurred in February 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Higher body mass index (BMI) is linked to a higher risk for estrogen receptor-positive breast cancer after menopause.

Initiation of GLP-1 receptor agonists was linked to fewer asthma exacerbations across overweight, obese, and morbidly obese patient cohorts.

Trader Joe’s and Ajinomoto Foods voluntarily recalled frozen meals nationwide after multiple consumer complaints about glass in the products.

Oral orforglipron demonstrated noninferiority and superiority to oral semaglutide for HbA1c reduction in adults with type 2 diabetes.

Maternal diabetes and being born large for gestational age are linked to a significantly higher risk for adult-onset multiple sclerosis in offspring.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.